ArticleBiotechnology reports (Amsterdam, Netherlands)2026
Validation of an automated total and viable cell counting for GMP-compliant production of human bone marrow stromal cells.
Article in Biotechnology reports (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow stromal cells (BMSCs) are classified as Advanced Therapy Medicinal Products (ATMPs) in the subcategory of Cell Therapy Medicinal Products (CTMPs), and the production of these cells for clinical use under good manufacturing practice (GMP) standards is regulated by the European Medicines Agency (EMA). To meet GMP standards for CTMPs, the accuracy and precision of cell-counting methods are essential for monitoring in-process quality and controlling clinical dosing. To achieve this purpose, we validated an automated cell-counting method for evaluating cell concentration and viability, enabling large-scale analysis and reducing analyst-associated variability. Automated cell counting was performed using the LUNA™ automated cell counter, and we validated the parameters against the hemocytometer using the ICH Q2R1 framework. The results showed that automated cell counting yielded acceptable accuracy (90-110%) and RSD (<10%). This demonstrates that LUNA™ automated cell counters may provide an efficient alternative for measuring BMSC cell concentration and viability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.